Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
Annals of the Rheumatic DiseasesPublished 29 August 2014Open access
T. Huizinga, Philip G. Conaghan, E. Martín‐Mola, Georg Schett, Howard Amital, Ricardo Machado Xavier
Citations110
SJR quartileQ1
SJR score5.73
SNIP4.44
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Treat-to-target strategies could be successfully implemented with TCZ to achieve sustained remission, after which TCZ was stopped.
Abstract
NCT00810199.
Keywords
Medicine
Annals of the Rheumatic DiseasesEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
5,775 Citations2017Josef S Smolen, Robert Landewé +47 more
These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
Arthritis Care & Research2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
1,792 Citations2012Jasvinder A. Singh, Daniel E. Fürst +28 more
The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Annals of the Rheumatic DiseasesEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
1,762 Citations2013Josef S Smolen, Robert Landewé +31 more
The 2010 European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and b DMARDs, respectively) have been updated and are intended to improve outcome in patients with RA.
Annals of the Rheumatic DiseasesComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
789 Citations2009Graeme Jones, Anthony Sebba +9 more
Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotRexate or biological agents has not previously failed.
Annals of the Rheumatic DiseasesStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
741 Citations2007Norihiro Nishimoto, Jun Hashimoto +7 more
Tocilizumab monotherapy was generally well tolerated and provided radiographic benefit in patients with RA and improved signs and symptoms.
Arthritis & RheumatismVery early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trial
533 Citations2005Mark Quinn, Philip G. Conaghan +8 more
Remission induction with infliximab plus MTX provided a significant reduction in MRI evidence of synovitis and erosions at 1 year, and functional and quality of life benefits were sustained, despite withdrawal of inflIXimab therapy, which may have significant implications for the optimal use of expensive biologic therapies.
The LancetMaintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
347 Citations2013Josef S Smolen, Peter Nash +12 more
Conventional or reduced doses of etanercept with methotrexate in patients with moderately active rheumatoid arthritis more effectively maintain low disease activity than does methotRexate alone after withdrawal of etAnercept.
Modern RheumatologyStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
335 Citations2008Norihiro Nishimoto, Nobuyuki Miyasaka +5 more
Tocilizumab monotherapy was well tolerated and provided an excellent clinical benefit in active RA patients with an inadequate response to low dose MTX.
Annals of the Rheumatic DiseasesAdding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
285 Citations2012Maxime Dougados, K. Kissel +10 more
No clinically relevant superiority of the TCZ+MTX add-on strategy over the switch to tocilizumab monotherapy strategy was observed and Meaningful clinical and radiographic responses were achieved with both strategies, suggesting that tocilizumab monotherapy might be a valuable treatment strategy in suitable RA patients.
Annals of the Rheumatic DiseasesDeciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change
280 Citations2004Karin Bruynesteyn, M Boers +3 more
In this setting the degree of progression that can be reliably detected above the measurement error is best determined by the smallest detectable change, and overestimated by the traditionally calculated smallest detectable difference.
The LancetAdjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
272 Citations2013Josef S Smolen, Paul Emery +9 more
Treatment to a stable low disease activity target resulted in improved clinical, functional, and structural outcomes, with both adalimumab-continuation and methotrexate-monotherapy.
Modern RheumatologyStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
271 Citations2009Norihiro Nishimoto, Nobuyuki Miyasaka +5 more
Annals of the Rheumatic DiseasesImpact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
219 Citations2011Moetaza M. Soliman, Darren M. Ashcroft +4 more
Annals of the Rheumatic DiseasesPatients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
200 Citations2010Benazir Saleem, Helen Keen +10 more
In patients in remission with low levels of imaging synovitis receiving combination treatment with a TNF blockers and MTX, immunological parameters and short duration of untreated symptoms were associated with successful cessation of TNF blocker therapy.
Lara D. VeekenRegistries in rheumatoid arthritis and autoimmune diseases: data from the French registries
174 Citations2010Xavier Mariette, Jacques‐Eric Gottenberg +2 more
The establishment of biological registries in rheumatic diseases, in France, with their different methods, has already provided additional data to controlled trials, mainly on the risk of severe infections and lymphoma.
Arthritis Research & TherapyClinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register
173 Citations2006Joachim Listing, Anja Strangfeld +7 more
It is found that biologics increase the chance to achieve clinical remission and a status of functional remission or at least physical independence in rheumatoid arthritis patients treated with either biologicics or conventional DMARDs.
Annals of the Rheumatic DiseasesClinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
151 Citations2014Maxime Dougados, K. Kissel +10 more
Despite a trend favouring the add-on strategy, these data suggest that both tocilizumab add- on and switch strategies led to meaningful clinical and radiographic responses.
Annals of the Rheumatic DiseasesDiscontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
124 Citations2011Maries van den Broek, Naomi B. Klarenbeek +7 more
The disease course after the cessation of infliximab in early rheumatoid arthritis patients with disease activity score (DAS)-steered treatment and to identify predictors of persistent low disease activity was described and smoking, long inflixIMab treatment duration and SE were independently associated with re-introduction of inflIXimab.
Annals of the Rheumatic DiseasesTocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
112 Citations2012Vivian P. Bykerk, Andrew J.K. Östör +10 more
In patients with RA who were DMARD-IR/TNFi-IR, tocilizumab ± DMARDs provided rapid and sustained efficacy without unexpected safety concerns.
Annals of the Rheumatic DiseasesCertolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
108 Citations2014Josef S Smolen, Paul Emery +8 more
Addition of CZP to non-biologic DMARDs is an effective treatment in RA patients with predominantly moderate disease activity, allowing low-disease activity or remission to be reached in a majority of the patients, however, the data suggest that CZp cannot be withdrawn in patients achieving remission.
Arthritis Care & ResearchTocilizumab as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs: Twenty‐four–week results of an open‐label, clinical practice study
63 Citations2012Michael E. Weinblatt, Joel Kremer +7 more
To assess the safety and tolerability of tocilizumab (TCZ) as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs (DMARDs) in patients with moderate to severe rheumatoid arthritis who had an inadequate response at study entry to their current treatment with biologic agents or DMARDs.
The Journal of RheumatologyUtilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study
63 Citations2009Sang Hyuck Lee, Hong Chang +4 more
PubMedDiscontinuation of biologics in patients with rheumatoid arthritis.
61 Citations2013Yoshiya Tanaka, Shintaro Hirata +2 more
Evidence from studies suggests that MTX-naïve, early RA patients can achieve sustained biologic-free remission with no functional or radiographic progression, after treatment with combination TNF inhibitors and MTX.
PubMedThe BeSt way of withdrawing biologic agents.
27 Citations2013Cornelia F Allaart, Willem F. Lems +1 more
Treat to target strategies using biologic agents should include strategies for discontinuation, suggesting that this possible in 1 in 4 patients, or more if infliximab was the initial treatment, who have had at least 6 consecutive months of low disease activity.